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Summary: Ochratoxin A is a mycotoxin produced by Aspergillus ochraceus and is a natural contaminant of moldy
food. Ochratoxin A has a number of toxic effects, some of which may be related to the changes in the cell
membrane. We measured the activities of 5 pancreatic, membrane bound enzymes in female Fisher rats that were
given low oral doses of ochratoxin A (120 Mg/kg body weight per day) during 20-35 days. The amount of toxin
corresponds to 1.5 mg/kg in the feed, daily. These doses are in the range of natural contamination found in feed.
The enzymes studied were alanine aminopeptidase, alkaline phosphatase, ecto-Ca2+/Mg2"l"-ATPase, γ-glutamyl
transferase and ecto-5f-nucleotidase. Treatment lasting 20 days caused a strong decrease in the activity of alanine
aminopeptidase, Ca2H~/Mg2+-ATPase and alkaline phosphatase to 0.76 ± 0.04, 0.53 ± 0.03 and 0.30 ± 0.02 of the
control values, respectively (p < 0.05). No significant changes in the activity of γ-glutamyl transferase and 51-
nucleotidase were observed. However, activity of alanine aminopeptidase returned to normal values after 35 days
of treatment, suggesting an adaptation of the organism, or a substitution of a released enzyme. Activities of alkaline
phosphatase and Ca2+/Mg2"H-ATPase remained significantly reduced to 0.42 ± 0.03 and 0.52 ± 0.04, respectively
(p < 0.01). We conclude that treatment of rats with low doses of ochratoxin A resulted in reduction of the activities
of the membrane bound enzymes, most probably by inducing their release, as a result of the impairment of the
functional integrity of cell membranes.
Introduction in the transport of organic anions and mitochondrial
- , . . . , . - , dysfunction in kidney (2—4). Inhibition of mito-Ochratoxin A is a nephrotoxic, hepatotoxic and terato- ί * . , · · j -j - u u ι ·j ,, υ , ,. r, , chondnal respiration and oxidative phosphorylation, asgenie mycotoxin produced by storage molds (chiefly by „ Λ Λ * · iL · j j' . .77 , TS · .77. \ - L c we" as decreased rate of protein synthesis and de-species of Aspergillus and Pemcilhum) on a variety of , ^^TA ^ - j -u j · ι -,. . _ t . ',. creased rate of RNA synthesis, were descnbed in livercommodities. Exposure to low concentrations of this ,_ _. . . A . . ,r. , . t , _ . . , . (5). The weak non-mutagenic genotoxicity and carci-toxin causes morphological and functional changes in . ° . Λ. ., " - . , . , . , nogemcity were shown for mice and rats and majorkidney of several domestic and experimental animals. ... / ^ O N T ^ i_^ . , ' , . , 0 target organs were kidney and liver (6—8). The mech-The toxin has also been found in human sera from . - 1 1 0 / j · · <*' ,. . _ _ „ , . , amsm responsible for the diverse toxic effects pro-
people living in areas where Balkan endemic nephropa- j u u * · AU * ^ u - j * - i j, r j . . Λ t ·τ_ι Λ - duced by ochratoxin A has not yet been identified,thy occurs, and it is suggested to be a possible detenm- ^ ' .. , . . . , J. . . ." t.' ,. - ,. ,1^ Competition with phenylalanine hydroxylase and othernant of this fatal human disease (I). r Λ ^ , u , , . u * * ·^ ' enzymes that accept phenylalanme as a substrate is
Numerous studies have identified the proximal tubule as based on the structural homology of ochratoxin A with
the most important intrarenal target and it is well docu^ this amino acid (9). Recently it was found that ochra-
mented that ochratoxin A causes glucosuria, a decrease toxin A greatly enhances the rate of NADPH depen-
dent lipid peroxidation (10). Enhanced peroxidation of
') This work has been supported by TTie -Ministry of Science and polyunsaturated fatty acids from membrane lipids
Technology of Croatia, project #1-07-102. might seriously impair cell membrane integrity, and
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produce structural and functional changes eventually
leading to cellular necrosis (11).
Ochratoxin A affects carbohydrate metabolism in rats,
producing an increase in blood glucose and a concomi-
tant decrease in glycogen in liver. The increase in the
blood glucose level was accompanied by decreased
levels of insulin during ochratoxin A treatment of rats
(2). Induction of hyperglycaemia associated with hypo-
insulinaemia were also produced with other mycotoxins
like terreic acid and pemitrem A (12). It has been shown
that 14C-labelled ochratoxin A accumulates in pancreas
after low dose intravenous injection (13, 14). Berndt et
al. found that repeated low doses given to rats produced
accumulation of the toxin in susceptible tissues, which
resulted in excessive weight loss and diarrhea, perhaps
related to the impairment of exocrine pancreatic func-
tion (15). However, although the toxicity of ochratoxin
A is extensively studied, only limited attention has been
directed toward changes produced in the pancreatic tis-
sue. Therefore -we decided to study effects of ochratoxin
A on the pancreas and especially on pancreatic plasma
membranes.
The main goal of this study was to determine changes
in the activities of enzymes bound to the pancreatic cell
membrane, as a result of administration of repeated low
doses of ochratoxin A (120 μg/kg body weight) during
20 and 35 days of treatment. This dose corresponds to
an average in the feed of 1.5 mg/kg each day, a concen-
tration that may be encountered in naturally contami-
nated food products (16). However, in our previous
work we observed changes in the activities of kidney
brush border enzymes induced by a similar regimen of
ochratoxin A treatment. Increased activities of rat renal
brush border enzymes in urine were found when low
doses of ochratoxin A were applied for 20 and 30 days
(17). The enzymes in this study were chosen as indicators
for the stability of pancreatic cell membranes. The se-
lected enzymes2) ecto-5'-nucleotidase, ecto-Ca2+/Mg2+-
ATPase, alanine aminopeptidase, alkaline phosphatase
and γ-glutamyl transferase exhibit different localization
and linkage on the phospholipid bilayer of the cell mem-
brane. A different degree of release of a particular enzyme
might be indicative for the mode of the toxic action of
ochratoxin A on the pancreatic cell membrane.
2) Enzymes:
Alanine aminopeptidase, (α-aminoacyl-peptide hydrolase, EC
3.4.11.2);
Alkaline phosphatase, (orthophosphoric monoester phosphohydro-
lase (alkaline optimum), EC 3.1.3.1);
γ-Glutamyl transferase, (γ-glutamyl-peptide : aminoacid γ-gluta-
myl transferase EC 2.3.2.2);
ecto-5'-nucleotidase, (S'-ribonucleotide phosphohydrolase EC
3.6.1.5)
ecto-Ca2+/Mg2+-ATPase, (ATP-phosphohydrolase, EC 3.6.1.5)
Materials and Methods
Materials
Ochratoxin A was obtained by biosynthesis from culture ofAsper-
gilliis sulphureus NRRL 4077 on wheat kernels with 40% humid-
ity. Isolation procedure was essentially according to 1. c. (18). The
white crystalline material was tested for .purity by thin-layer chro-
matography and then identified as abright blue fluorescent spot
under short wave UV light (19). The concentration of ochratoxin
A was determined spectrophotometricaliy at 333 run in methanol,
assuming a molar absorbance of 550 m2/mol (1).
Animals
Adult albino female rats of Fisher strain weighing between 150 and
200 g were used for the experiments. The animals were given food
and water ad libitum, (food - standard laboratory pellets, declared
not to contain mycotoxins, PLIVA d.d., Zagreb, Croatia). Rats
were divided into experimental (n = 10) and control (n = 5)
groups.
Group A - 20 days treatment
Daily dose of ochratoxin A 120 μg/kg body weight (dissolved in
a volume of 0.5 ml of 0.051 mmol/1 NaHCO3) was administered
to experimental animals each morning by gastric intubation. Ani-
mals were sacrificed after 20 days of treatment. Total amount of
ochratoxin A given was 400 μg ochratoxin A per animal.
Group B — 35 days treatment
The animals received the same daily dose during 35 days, corre-
sponding to total amount of 720 μg ochratoxin A per animal.
Controls
The control animals received daily dose of 0.5 ml of 0.051 mmol/i
for 20 and 35 days, respectively.
Isolation of pancreatic plasma membranes
Rats were sacrificed by cervical dislocation after light ether anes-
thesia. Pancreas was homogenized at 4 °C in an Ultra-turrax ho-
mogenizer in 5 mmol/1 Tris-Hepes buffer (pH 7.0), containing 280
mmol/1 mannitol, 10 mmol/1 KC1, 1 mmol/1 MgCl2, 1 mmol/1 ben-
zamidine and 0.1 g/1 soybean trypsin inhibitor. The homogenates
were centrifuged for 15 min at 1000 g and supernatant was further
centrifuged at 13000g for 20 min. Pellets containing cell mem-
branes were resuspended in 1 ml of the same buffer, vesiculated
and centrifuged for 30 min at 18 000 g. The final pellet, containing
plasma membranes was resuspended and vesiculated in 0.5 ml of
the 500 mmol/1 Tris-Hepes buffer (pH 7.4) and saved for enzyme
analysis. The analyses of the enzyme activity were performed with
the fresh membrane preparations.
Enzyme assays
Determination of the activity of ecto-Ca2"l"/Mg2+-ATPase and ecto-
5'-nucleotidase was performed in 0.5 ml of reaction medium con-
taining (final concentrations) 50 mmol/1 Tris-Hepes pH 7.4, 10
mmol/1 KC1 and inhibitors of other ATPases, 0.1 mmol/1 levami-
sole, 0.1 mmol/1 ouabain, 0.1 mmol/1 N-ethyl-maleimide, 0.1
mmol/1 sodium azide, 1 mmol/1 MgCl2 and 0.030 mg of proteins
in the presence of 1 mmol/1 substrate. Substrate for the determina-
tion of ecto-Ca2+/Mg2+-ATPase activity was 1 mmol/1 ATP and
for ecto-5'-nucleotidase activity 1 mmol/1 AMP (20). The liberated
inorganic phosphate was measured by 'the method of Fiske and
SubbaRow (21). Alanine aminopeptidase? was determined according
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to Jung & Scholz (22) with 0.7 mmol/1 of alanine- -naphthylamide
as substrate, γ-glutamyl transpeptidase according to SzaSz (23) with
Y-glutamyl-4-nitroanilide as substrate and alkaline phosphatase ac-
cording to IFCC recommendations.
Protein concentration was determined according to Bradford (24)
using bovine serum albumin as a standard. Spectrophotometric
measurements were performed on the Unicam SP 8 X 100 Spectro-
photometer.
Chemicals
All biochemicals, including coenzymes, substrates and auxiliary
enzymes were of analytical grade purchased from Sigma Chem.
Co. (St Louis, Mo, USA), or Boehringer (Mannheim, Germany).
Statistics
The data are presented as mean values ± SEM.
Significance of the difference was tested by Mann-WIiitney U-test.
Values were considered significantly different if p < 0.05.
Results
In this paper we studied the changes that occur in the
pancreatic plasma membrane following 3—5 weeks of
daily, oral application of low doses of ochratoxin A to
rats. Activities of membrane bound ecto-Ca2"l"/Mg24"-
ATPase, ecto-S'-nucleotidase, alanine aminopeptidase,
γ-glutamyl transferase and alkaline phosphatase were
selected as indicators of the functional integrity of the
cell membrane.
In the preliminary experiments we found detectable con-
centration of ochratoxin A in the pancreas following
acute and prolonged treatment with low doses of the
toxin. When inspected under UV light, pancreatic tissue
showed fluorescence characteristic for the presence of
ochratoxin A (results not shown). The serum level of
ochratoxin A was measured according to Hult et al., and
was found to be 300 μg/l following 35 days of treatment
(1). Table 1 shows the effects of ochratoxin A on body
weight, pancreas weight and protein content in pancre-
atic tissue. The experimental animals that were receiving
daily doses of 120 μg/kg body weight of ochratoxin A
during 35 days showed a significant decrease in the
body weight gain of about 75% and decreased protein
concentration in the homogenates prepared from the
pancreatic tissue, in comparison to the control group.
We suppose that the combination of the reduction in the
food intake and inhibition of the protein synthesis might
both be contributing to the effects measured.
Data concerning activities of the enzymes in the pancre-
atic plasma membrane are very scarce, therefore we first
had to establish control values for the enzyme activities
that would be used as the reference for the comparison.
Table 2 represents the activities of: ecto-Ca2+/Mg2+-
ATPase, ecto-5'-nucleotidase, alanine aminopeptidase,
γ-glutamyl transferase and alkaline phosphatase in pan-
creatic plasma membrane of control animals. The activ-
ity of the enzymes tested did not significantly change
between the two experimental time points.
Changes in the activities of the pancreatic membrane
bound enzymes following 20 and 35 days of treatment,
respectively, are shown in the figure 1. From the results
presented, it is evident that ochratoxin A produced a
Tab. 2 Enzyme activities in pancreatic plasma membranes of
control rats
Enzyme Enzyme activity ± SEMa
(μηιοί min"1 mg"1 protein)
















a Data are presented as mean ± SEM for the control animals that
were receiving 0.5 mi of 0.051 mmol/1 NaHCO3 for 20 days
(n = 5) and 35 (n = 5), respectively.
Tab. 1 Effects of ochratoxin A treatment on the gain in body weight, pancreas weight and protein




























Data are presented -as mean ± SEM from control (n = 5) and c Ochratoxin A treated animals received ochratoxin A at a daily
treated (n = 10) animals. dose of 120 μg/kg body weight dissolved in 0.5 ml of 0.051 mmol/1
a The gain in the body weight was measured for 20 and 35 days, NaHCO3, for the indicated number of days.
respectively. d Statistical significance of the difference between treated and con-
b Controls received 0.5 ml of 0.051 mmol/1 NaHCO3, daily. trol rats at the confidence level p < 0.05.
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γ-Glutamyl- AJanine Alkaline ATPase 5-Nucleo-
transferase amino- phosphatase tidase
peptidase
Fig. 1 Enzyme activities in isolated pancreatic plasma mem-
branes of rats treated with ochratoxin A for 20 (D) and 35 (@) days.
Data are presented as fraction of control values (mean ± SEM)
from 10 separate membrane preparations.
(*) Statistical significance of the difference between treated and
control rats at the confidence level p < 0.05.
decrease in alanine aminopeptidase, alkaline phospha-
tase and ecto-Ca2+/Mg2+-ATPase, already after 20 days
of treatment. Activities of alanine aminopeptidase, ecto-
Ca2+/Mg2+-ATPase and alkaline phosphatase were re-
duced in comparison to the controls, and the fraction of
the remaining activities were 0.76 ± 0.04, 0.53 ± 0.03
and 0.30 ± 0.02, respectively. Changes in the activities
of γ-glutamyl transferase and 5'-nucleotidase were not
statistically significant. In the prolonged course of treat-
ment, following 35 days of ochratoxin A intoxication,
only the activity of alanine aminopeptidase returned to
control values. However, it is worth mentioning that 5'-
nucleotidase, alanine aminopeptidase and γ-glutamyl
transferase could be found in cytosolic and in membrane
bound fractions in the cell (25-27). The observed nor-
malization may be a result of the novel redistribution of
the enzyme isoforms between those two compartments.
In contrast to these results catalytic concentration of
ecto-Ca2+/Mg2+-ATPase and alkaline phosphatase re-
mained significantly reduced at 0.56 ± 0.04 and 0.42
± 0.03 of the control values, on day 35 of the experi-
ment. It seems that normalization of catalytic concentra-
tions of Ca2+/Mg2+-ATPase and alkaline phosphatase
might require the synthesis of new protein molecules, a
process that is seriously impaired by ochratoxin A treat-
ment (5). Consequently, these enzyme activities re-
mained significantly reduced. Similar results were ob-
served in kidney (28, 29).
Discussion
Biochemical changes that occur following treatment
with ochratoxin A involve almost all organs and tissues.
It has been well documented that toxin accumulates in
the various tissues. Pharmacokinetic studies have shown
that ochratoxin A is distributed in two kinetically dis-
tinct compartments in rats, the central compartment cor-
responding to well perfused organs such as kidney, liver,
spleen, brain, lung, heart, pancreas and testes and a pe-
ripheral compartment comprising of skin, muscle, fat
and eyes (13, 30). The distribution pattern of ochratoxin
A in the rats and mice was shown to be very similar
(31). A different response to ochratoxin A administra-
tion was observed when either a single or repeated doses
were applied. Small doses injected repeatedly were re-
quired for the production of the severe changes in renal
function, excessive weight loss and diarrhea. Deposition
of toxin in the tissues was the consequence of the pro-
longed retention of ochratoxin A in the circulation, due
to its binding to the plasma proteins (32-34).
Accumulation of the toxin in pancreatic tissue has been
shown to be connected with lowered insulin concentra-
tions, possibly as a result of the toxin induced inhibition
of synthesis and/or release of the hormone from -cells.
The observed diabetogenic effects of ochratoxin A were
attributed to the reduced level of glycolysis and glyco-
genesis and enhancement of gluconeogenesis and glyco-
genolysis (2).
In our previous studies we found that treatment with low
doses of ochratoxin A over a period of 20 and 30 days
affected activities of γ-glutamyl transferase, alanine
aminopeptidase and alkaline phosphatase in kidney
brush border membranes (17). These time points were
found to be informative for the subchronical regimen of
treatment. It was shown by Kane et al. that activities
of renal, membrane bound enzymes such as γ-glutamyl
transferase, leucine aminopeptidase, and alkaline phos-
phatase were significantly reduced, following subchroni-
cal ochratoxin A treatment (28).
Since it has been shown that ochratoxin A accumulated
in the pancreatic tissue, we followed the activity of the
same enzymes in pancreas, repeating the low dosage
regimen, which results in deposition of the toxin in sus-
ceptible tissues. We included measurement of the activ-
ity of ecto-Ca2+/Mg2+-ATPase and ecto-S'-nucleotidase
in this study since these two membrane enzymes might
be involved in the metabolism of extracellular ATP and
possible regulation of the ATP-dependent Ca2+ uptake
in the pancreas. Calcium ions play an important role
in the stimulation of enzyme secretion from exocrine
pancreas. It has been proposed that a secretagogue-in-
duced rise in cytosolic free Ca2+ triggers enzyme re-
lease from pancreatic acinar cells (35, 36). Activity of
Ca2+/Mg2+^ATPase was shown to be involved in the
exocytosis of the pancreatic enzymes from the mem-
brane bound zymogen granules (37). However, the exact
physiological function of ecto-Ca2+/Mg2+-ATPase ac-
tivity is not clear. It is assumed that it may simply
Eur J Clin Chem Clin Biochem 1995; 33 (No 10)
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serve to regulate extracellular ATP concentration in the
vicinity of the plasma membrane (38). As it has been
shown for renal proximal tubule a concerted action of
ecto-Ca2"VMg24"-ATPase together with ecto-5-nucleoti-
dase is able to hydrolyze extracellular ATP to AMP
yielding eventually adenosine as the product of the reac-
tion (20).
Our results revealed reduction in the body weight gain,
decrease in the protein concentration in the pancreatic
homogenates and decreased activities of alanine amino-
peptidase, alkaline phosphatase and ecto-Ca2+/Mg2+-
ATPase (tab. 1 and fig. 1). The observed reductions in
the enzyme activities might be reflecting the decrease in
the DNA and protein synthesis that are produced by the
ochratoxin A treatment (5, 39, 40). Decrease of the en-
zyme activity could not be explained in terms of the
mode of attachment to the cell membrane. Affected en-
zymes belong to groups that are bound to the membrane
in different ways.
Leakage of enzymes from the damaged cell membrane
is mainly influenced by the mode of attachment of the
particular enzyme protein to the hydrophobic phospho-
lipid membrane structure. The simplest form of attach-
ment is exemplified by γ-glutamyl transferase and ala-
nine aminopeptidase, in which the terminal sequence of
hydrophobic amino acids is inserted into the membrane.
There it is secured by hydrophobic interactions between
the amino acids and the lipid components of the mem-
brane. A more complex system refers to the attachment
of ectoenzymes like S'-nucleotidase, Ca2+/Mg2+-AT-
Pase and alkaline phosphatase. These enzymes are an-
chored in the membrane through the glycan phosphati-
dylinositol moiety that is linked to the carboxy terminus
of the polypeptide chain. Release of the enzyme may be
influenced either by detergent mediated solubilisation,
by enzyme cleavage (protease or phospholipase), or by
the fragmentation of the membrane structure (41).
Activity of alanine aminopeptidase was already signifi-
cantly affected after 20 days, but it returned to higher
than normal levels in the following 15 days, in spite of
the continuation of the ochratoxin A treatment. That was
a surprising finding since ochratoxin A treatment pro-
duces a decrease hi DNA and protein synthesis.
Increased level of membrane bound alanine aminopepti-
dase might be originating from the cytosolic fraction. Acknowledgements
However, γ-glutamyl transferase, bound to the mem-
brane in a similar way, did not exhibit significant
changes at the same time. From the group of more
tightly bound enzymes only ecto-Ca2+/Mg2+-ATPase
and alkaline phosphatase were significantly reduced
while ecto-5'-nucleotidase remained unchanged.
In his recent review Moss showed that alkaline phospha-
tase could be released either by phospholipase action or
by membrane fragmentation (42). It was shown before
that both γ-glutamyl transferase and 5f-nucleotidase
could be solubilized at increased amounts in cholestasis,
presumably by a detergent-mediated action of bile acids.
There are no reports that ochratoxin A treatment is asso-
ciated with increased levels of bile acids in blood or
liver, much less in the pancreatic tissue. The simplest
explanation for the reduced level of the membrane
bound enzyme activities observed in this study is a pos-
sible alteration of membrane lipid organization and
potential membrane fragmentation. Perturbation of the
liver microsomal membranes has been attributed to och-
ratoxin A induced increased NADPH-dependent lipid
peroxidation (29). In order to gain further insight into
the effects of ochratoxin A an human and animal health
in more detail, the influence of repeated low doses on
the endocrine and exocrine function of the pancreatic
cells must be further investigated.
Conclusions
The observed decrease in the catalytic concentration of
the membrane bound enzymes measured suggests that
ochratoxin A is connected with an impairment in the
structure and function of the pancreatic plasma mem-
brane. Acute effects reflected in the reduction of the en-
zyme activities could be subsequently normalized for
alanine aminopeptidase in spite of the continuation of
the daily ochratoxin A treatment. However, reduction
in the activities of the Ca2+/Mg2"l"-ATPase and alkaline
phosphatase remained unchanged. From the above ob-
servations we conclude that ochratoxin A exerts its toxic
effects on pancreas by diminishing catalytic concentra-
tions of the membrane bound enzymes, most probably
by inducing the release of the enzymes as a result of the
impairment of the functional integrity of the cell mem-
brane.
The present work has been supported by The Ministry of Science
and Technology of Croatia, project #1-07-102.
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